MWA
VRTX icon

MN Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

MN Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Sell
3,098
-59
-2% -$26.1K 0.66% 27
2026
Q1 		$1.41M Buy
3,157
+7
+0.2% +$3.26K 0.69% 28
2025
Q4 		$1.43M Buy
3,150
+266
+9% +$115K 0.72% 26
2025
Q3 		$1.13M Buy
2,884
+476
+20% +$199K 0.6% 35
2025
Q2 		$1.07M Sell
2,408
-16
-0.7% -$7.37K 0.62% 38
2025
Q1 		$1.18M Sell
2,424
-539
-18% -$251K 0.69% 38
2024
Q4 		$1.19M Buy
2,963
+235
+9% +$109K 0.67% 34
2024
Q3 		$1.27M Buy
2,728
+65
+2% +$31.2K 0.72% 31
2024
Q2 		$1.25M Buy
2,663
+33
+1% +$14.3K 0.72% 31
2024
Q1 		$1.1M Hold
2,630
– – 0.68% 32
2023
Q4 		$1.07M Buy
+2,630
New +$972K 0.74% 32

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MN Wealth Advisors's VRTX Position: Q2 2026 in Review

MN Wealth Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q2 2026, selling an estimated $26.1K and leaving 3,098 shares worth $1.54M. The position accounts for 0.66% of the portfolio, ranked #27.

MN Wealth Advisors first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • MN Wealth Advisors held 3,098 shares of Vertex Pharmaceuticals worth $1.54M as of Q2 2026.
  • MN Wealth Advisors sold 59 Vertex Pharmaceuticals shares in Q2 2026, an estimated $26.1K.
  • Vertex Pharmaceuticals made up 0.66% of MN Wealth Advisors's portfolio in Q2 2026, its #27 holding.
  • MN Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on MN Wealth Advisors's 13F filing for Q2 2026, filed 23 Jul 2026.